Cinpanemab
Modify Date: 2024-04-06 17:29:56
Cinpanemab structure
|
Common Name | Cinpanemab | ||
|---|---|---|---|---|
| CAS Number | 2094516-02-4 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CinpanemabCinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease[1][2]. |
| Name | Cinpanemab |
|---|
| Description | Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease[1][2]. |
|---|---|
| Related Catalog | |
| Target |
α-synuclein[1] |
| In Vitro | Cinpanemab 对聚合形式的 α-syn 具有高度选择性，对纤维状重组 α-syn 的表观亲和力至少比单体重组 α-syn 高 800 倍，并且对人 PD 脑组织有强烈的偏好[2]。 |
| In Vivo | Cinpanemab (30 mg/kg; 腹腔注射) 改善 α-syn PFF 接种小鼠模型中的 PD 样表型[2]。 Animal Model: C57BL/6JRccHsd WT mice, transgenic M83 mice expressing human α-syn A53T, and transgenic bacterial artificial chromosome mice expressing human α-syn A53T were anesthetized and stereotaxically injected with α-syn preformed fibrils (PFFs) into the right forebrain[2] Dosage: 30 mg/kg Administration: Intraperitoneal (i.p.) injections 2-3 times prior to α-syn PFF injection and weekly post-injection until time of sacrifice Result: Attenuated the spreading of α-syn pathology, rescued motor impairments, and reduced the loss of dopamine transporter density in dopaminergic terminals in striatum. |
| References |
| No Any Chemical & Physical Properties |